Next Article in Journal
Advances in Drug Design Based on the Amino Acid Approach: Taurine Analogues for the Treatment of CNS Diseases
Previous Article in Journal
Mitochondria-Targeted Antioxidant SS31 Prevents Amyloid Beta-Induced Mitochondrial Abnormalities and Synaptic Degeneration in Alzheimer’s Disease
Previous Article in Special Issue
The Tissue Selective Estrogen Complex: A Promising New Menopausal Therapy
Pharmaceuticals 2012, 5(10), 1120-1127; doi:10.3390/ph5101120
Article

Norethindrone Acetate in the Medical Management of Adenomyosis

1,2,* , 1, 1, 1 and 3
1 Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA 2 Department of Obstetrics and Gynecology, Kings County Hospital Center, 451 Clarkson Avenue, Brooklyn, NY 11203, USA 3 Scientific Computing Center, SUNY Downstate Medical Center, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
* Author to whom correspondence should be addressed.
Received: 8 July 2012 / Revised: 4 October 2012 / Accepted: 15 October 2012 / Published: 22 October 2012
(This article belongs to the Special Issue Hormone Therapy)
View Full-Text   |   Download PDF [182 KB, uploaded 22 October 2012]   |   Browse Figure

Abstract

The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings.
Keywords: norethindrone acetate; adenomyosis; dysmenorrhea norethindrone acetate; adenomyosis; dysmenorrhea
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Muneyyirci-Delale, O.; Chandrareddy, A.; Mankame, S.; Osei-Tutu, N.; Gizycki, H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals 2012, 5, 1120-1127.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert